Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view

Cavalier, Étienne; Bekaert, Anne-Catherine; Carlisi, Agnès; Legrand, Delphine; Krzesinski, Jean-Marie

doi:10.1515/cclm.2011.044

Cited by 28 publications

(21 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…with an NGAL declared concentration of 198 and 488 ng/mL, while for the Architect assay, we refer to recently published data [19]. The new nephelometric method, applied on Dimension Vista, showed an imprecision level similar to that specified by the manufacturer (Table 1) and comparable to that of Architect and other prior studies [19][20][21]30]. More imprecision was observed with the turbidimetric method on Advia 2400, both for a bias in the target values and in the CV%, particularly in run 2 (Table 2).…”

Section: Discussionsupporting

confidence: 58%

A comparison of three commercial platforms for urinary NGAL in critically ill adults

Cruz

Virzì²,

Brocca³

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

All three methods for uNGAL showed acceptable performance for the tested parameters and are comparable with each other at clinically relevant cutoffs. However, Architect yields lower results than the other two methods, with a bias more pronounced at higher uNGAL concentrations, suggesting additional standardization efforts will likely be necessary to better harmonize the uNGAL methods at various clinically relevant cutoffs.

show abstract

Section: Discussionsupporting

confidence: 58%

A comparison of three commercial platforms for urinary NGAL in critically ill adults

Cruz

Virzì²,

Brocca³

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…A published study evaluating the Abbott NGAL assay and aspects of sample stability reported excellent reproducibility and precision although recovery, linearity and selectivity were not examined. 16 A small study confirmed the acceptable variability over the range of the Abbott assay 19 although interestingly also highlighted potential issues with the measurement range of the Biosite Triage NGAL assay for plasma NGAL. An extensive validation of the BioPorto ELISA reported generally excellent performance with urine and plasma, although problems with inter-batch variability were highlighted.…”

Section: Discussionmentioning

confidence: 84%

A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine

et al. 2013

View full text Add to dashboard Cite

Background: Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker for acute kidney injury that is beginning to be used in clinical practice in addition to research studies. The current study describes an independent validation and comparison of five commercially available NGAL assays, focusing on urine samples. This is an essential step in the translation of this marker to clinical use in terms of allowing valid inter-study comparison and generation of robust results. Methods: Two CE (Conformité Europé enne)-marked assays, the NGAL Test (BioPorto) on Siemens ADVIA w 1800 and the ARCHITECT Urine NGAL assay on i2000SR (Abbott Laboratories), and three research-use-only (RUO) ELISAs (R&D Systems, Hycult and BioPorto) were evaluated. Imprecision, parallelism, recovery, selectivity, limit of quantitation (LOQ), vulnerability to interference and hook effect were assessed and inter-assay agreement was determined using 68 urine samples from patients with various renal diseases and healthy controls. Results: The Abbott and R&D Systems assays demonstrated satisfactory performance for all parameters tested. However for the other three assays evaluated, problems were identified with LOQ (BioPorto/ADVIA w ), parallelism (BioPorto ELISA) or several parameters (Hycult). Between-method agreement varied with the Hycult assay in particular being markedly different and highlighting issues with standardization and form of NGAL measured. Conclusions: Variability exists between the five NGAL assays in terms of their performance and this should be taken into account when interpreting results from the various clinical or research studies measuring urinary NGAL.

show abstract

“…7 -9 NGAL can be measured in both urine and plasma. 10 NGAL requires further evaluation in different clinical settings but evidence so far suggests it to be a promising biomarker. 11 -14 Abbott Diagnostics (Abbott Park, IL, USA) has developed an automated urinary NGAL assay for use on the ARCHITECT analyser.…”

Section: Introductionmentioning

confidence: 99%

Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin

2012

View full text Add to dashboard Cite

Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is emerging as a promising new biomarker for the early identification of acute kidney injury (AKI). We have determined a reference range in a large healthy population. In addition, as NGAL is a neutrophil-related protein, we investigated whether the presence of leukocyturia has the potential to significantly alter the specificity of NGAL in the diagnosis of AKI. Methods: One hundred and seventy-four subjects (100 men, 74 women ranging from 19 to 88 y) were included in the reference population. Urinary NGAL was analysed on the Abbott ARCHITECT and results expressed in mass (mg/L) and also normalized to urinary creatinine (mg/mmol). Fifty-two leukocyturic urine samples were also analysed for NGAL. Results: The 95th centile for NGAL was determined to be 107 mg/L (13 mg/mmol). There were significant gender-related differences for NGAL, with women having higher concentrations. There were significant age-related differences for NGAL between the 40-59 and 60-88 y age categories. There were significant age-related differences between the ,40 and 60-88 y categories when NGAL was normalized to creatinine. In addition, we found significantly higher concentrations of NGAL in leukocyturia (P , 0.0001). Conclusions: We have established a 95th centile cut-off for urinary NGAL in a reference population. We have demonstrated the important potential interference of leukocyturia in confounding the interpretation of NGAL in the diagnosis of AKI.

show abstract

Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view

Cited by 28 publications

References 8 publications

A comparison of three commercial platforms for urinary NGAL in critically ill adults

A comparison of three commercial platforms for urinary NGAL in critically ill adults

A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine

Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin

Contact Info

Product

Resources

About